RNY5

Summary

RNY5 (RNA, Ro60-associated Y5, HGNC:10248) is a gene on chromosome 7q36.1.

Biomarker of congestive heart failure.

Source: NCBI Gene 6090 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 1 total

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10248
Approved symbol	RNY5
Name	RNA, Ro60-associated Y5
Location	7q36.1
Locus type	RNA, Y
Status	Approved
Aliases	hY5
OMIM	601824
Entrez	6090
RNAcentral	URS00004A2461 — ncRNA, 84 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• Y5 RNA uniquely copurified ribosomal protein L5 and its binding partner 5S RNA (PMID:18056422)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1002165083 (7:148941902 A>G), RS1002395181 (7:148941433 C>G), RS1002730555 (7:148939707 T>C), RS1002761856 (7:148940141 C>G), RS1002763417 (7:148941449 G>A,C), RS1004256518 (7:148941245 T>C), RS1004597307 (7:148941957 C>A), RS1005318336 (7:148941567 G>A,C), RS1005708570 (7:148940058 T>C,G), RS1006197137 (7:148940478 C>T), RS1006962608 (7:148940244 T>C), RS1011611532 (7:148941879 T>C), RS1011785459 (7:148939684 G>A), RS1012242520 (7:148941575 CTAA>C), RS1016081629 (7:148941462 A>C,G)

Disease associations

OMIM: gene MIM:601824 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST008163_312	Height	7.000000e-12
GCST008163_399	Height	2.000000e-06
GCST012226_658	Waist circumference adjusted for body mass index	2.000000e-08
GCST012227_140	Hip circumference adjusted for BMI	7.000000e-09
GCST012227_141	Hip circumference adjusted for BMI	6.000000e-10
GCST90020028_285	Hip circumference adjusted for BMI	2.000000e-17
GCST90020028_286	Hip circumference adjusted for BMI	1.000000e-17
GCST90020028_287	Hip circumference adjusted for BMI	3.000000e-10
GCST90020028_288	Hip circumference adjusted for BMI	6.000000e-16
GCST90020029_903	Waist circumference adjusted for body mass index	1.000000e-10
GCST90020029_904	Waist circumference adjusted for body mass index	1.000000e-08
GCST90020029_905	Waist circumference adjusted for body mass index	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone	decreases degradation	1
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone	decreases degradation	1
Anisomycin	increases degradation	1
Dactinomycin	increases degradation	1
Testosterone	increases expression	1
Valproic Acid	increases methylation	1
Zinc Sulfate	decreases degradation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.